AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $205.00
- 52-wk high
- $241.78
- High
- $207.84
- 52-wk low
- $160.60
- Low
- $202.12
- Prev close
- $207.66
- Mkt cap
- $140.70B
- P/E
- 35.7x
- Volume
- 3.28M
- Fwd P/E
- 21.6x
- Beta
- 0.81
- Div yield
- 0.72%
- P/S
- 5.6x
- P/B
- 2.7x
- Profit margin
- +16.0%
- Op margin
- +19.8%
- ROE
- +7.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 5.4% above what analysts expected.
Earnings per share
$1.84 expected
Revenue
No comparable estimate
Reports Oct 20, 2026, in 38 days
EPS expected
$1.83 to $1.99
Revenue expected
20 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $6.05B | $6.84B | $5.95B | $6.26B |
| Cost of what it sold | $2.53B | $2.87B | $2.36B | $2.65B |
| Gross profit | $3.52B | $3.97B | $3.59B | $3.61B |
| What it spent | ||||
| Research and development | $378.0M | $438.0M | $387.0M | $412.0M |
| Sales and admin | $1.99B | $2.03B | $1.86B | $2.07B |
| Total operating expenses | $2.37B | $2.46B | $2.25B | $2.48B |
| What was left | ||||
| Operating profit | $1.15B | $1.50B | $1.34B | $1.13B |
| Interest on debt | $67.0M | $55.0M | $63.0M | $107.0M |
| Profit before tax | $1.08B | $1.37B | $1.24B | $1.08B |
| Tax | $168.0M | $176.0M | $206.0M | $208.0M |
| Net profit | $908.0M | $1.20B | $1.03B | $870.0M |
| EBITDA | $1.76B | $2.05B | $1.49B | $1.84B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Danaher Corp. stock underperforms Thursday when compared to competitors
BearishSep 10Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
BullishSep 9BWS Financial initiates Twist Bioscience stock with sell rating
NeutralSep 9UBS assumes coverage on Danaher stock with buy rating, $250 target
BullishSep 9UBS assumes coverage on Danaher stock with buy rating, $250 target
BullishSep 9Danaher Corp. stock outperforms competitors despite losses on the day
Leans bearishSep 8How Danaher Corporation (DHR) Affects Rotational Strategy Timing
BearishSep 8Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others
Leans bullishSep 8
Macro
31 macro signals shaping DHR right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results